Rheumatologist Rachelle Buchbinder, AO, MBBS (Hons), MSc, PhD, discusses reducing overdiagnosis, overtreatment, low-value care and waste in medicine.
An Inside Look at the Advocacy Leadership Conference
At this year’s Hill Day, attendees will receive in-depth training on Medicare reimbursement and hear from Rep. Larry Bucshon, MD, (R-Ind.) about his perspective on the issue as a physician in Congress.
Advocacy Leadership Conference to Support Inflation-Linked Medicare Payment Increases
On May 7, ACR leaders from the Board of Directors, committees and more will to go to Capitol Hill and ask lawmakers to support legislation that would stabilize Medicare reimbursement for physicians.
CMS Updates the Medicare Conversion Factor
The Consolidated Appropriations Act, 2024 increased the Medicare conversion factor by 1.68% effective March 9, bringing it to $33.2875 for March 9–Dec. 31, 2024.
UnitedHealthcare Updates Reimbursement for Infliximab Biosimilars
On April 1, UnitedHealthcare updated reimbursement for infliximab biosimilars in response to concerns that formulary requirements are leaving practices underwater.
Community Practice Rheumatology Can Enable Lasting Relationships
Benjamin Widener, MD, FACP, has found a niche in community practice rheumatology in his hometown in Wyoming. As the lone rheumatologist serving the community, he has the opportunity to develop lasting therapeutic relationships.
My Experience at the Rheumatology Research Workshop
Dr. Mrinalini Dey of London was invited to present her research at the 2023 Rheumatology Research Workshop in Orlando. She describes the experience here.
Poly-Refractory Rheumatoid Arthritis: An Uncommon Subset of a Difficult-to-Treat Disease
Difficult-to-treat rheumatoid arthritis (RA) is defined as the failure of two or more classes of biologic or targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) to control active or progressive disease in patients with RA. Between 5 and 20% of patients with RA have difficult-to-treat RA.
FDA Proposal for Biosimilar Use in 2025 Budget
A proposal for biosimilar use in the 2025 budget would allow substitution of any biosimilar for its reference product without an interchangeable designation. The hope is to increase biosimilar uptake, with the subsequent potential to increase product “competition, access and affordability.”1 In the 2025 budget proposal, the Biden administration noted that the legal distinction between…
The Biases We Don’t Know We Hold
Implicit bias can affect patient care at the physician level when they’re making treatment decisions and at the healthcare organization level when they’re choosing new hires. Here are insights into strategies rheumatologists can use to become aware of, and question, their implicit biases.
- « Previous Page
- 1
- …
- 40
- 41
- 42
- 43
- 44
- …
- 816
- Next Page »